of Asia. Here we report the whole-exome or targeted deep sequencing of 139 paired ESCC cases, and analysis of somatic copy number variations (SCNV) of over 180 ESCCs. We identified previously uncharacterized mutated genes such as FAT1, FAT2, ZNF750 and KMT2D, in addition to those already known (TP53, PIK3CA and NOTCH1). Further SCNV evaluation, immunohistochemistry and biological analysis suggested their functional relevance in ESCC. Notably, RTK-MAPK-PI3K pathways, cell cycle and epigenetic regulation are frequently dysregulated by multiple molecular mechanisms in this cancer. Our approaches also uncovered many druggable candidates, and XPO1 was further explored as a therapeutic target because it showed both gene mutation and protein overexpression. Our integrated study unmasks a number of novel genetic lesions in ESCC and provides an important molecular foundation for understanding esophageal tumors and developing therapeutic targets.
Esophageal squamous cell carcinoma (ESCC) is prevalent worldwide and particularly common in certain regions
of Asia. Here we report the whole-exome or targeted deep sequencing of 139 paired ESCC cases, and analysis of somatic copy number variations (SCNV) of over 180 ESCCs. We identified previously uncharacterized mutated genes such as FAT1, FAT2, ZNF750 and KMT2D, in addition to those already known (TP53, PIK3CA and NOTCH1). Further SCNV evaluation, immunohistochemistry and biological analysis suggested their functional relevance in ESCC. Notably, RTK-MAPK-PI3K pathways, cell cycle and epigenetic regulation are frequently dysregulated by multiple molecular mechanisms in this cancer. Our approaches also uncovered many druggable candidates, and XPO1 was further explored as a therapeutic target because it showed both gene mutation and protein overexpression. Our integrated study unmasks a number of novel genetic lesions in ESCC and provides an important molecular foundation for understanding esophageal tumors and developing therapeutic targets.
ESCC is one of the most common malignant diseases in the world and especially in China, where it is the fourth most common cause of cancerrelated deaths 1 . Unlike that of cancers that have been extensively studied, such as breast and colon cancers, the outcome of ESCC remains unchanged during the last several decades, with a five-year survival rate ranging from 15% to 25% (ref. 2) . We and others have revealed in ESCC frequent somatic copy number variations (SCNV) involving 3q26 (ref. However, in general, understanding of the genomic abnormalities in this disease is limited to studies of small cohorts 4, 6, 7, [9] [10] [11] [12] , including a recent whole-exome sequencing approach of 12 ESCCs 8 . Thus, a compelling need exists to extensively identify genomic abnormalities underlying ESCC, elucidate its molecular basis and guide the development of effective targeted therapies.
We first sequenced whole exomes (WES) of 20 matched ESCC germline and tumor pairs (discovery cohort, mean coverage 79×, Supplementary Tables 1a and 2a ). Transcriptome sequencing (RNA-seq) was also performed on 4 of these 20 tumors. A total of 1,186 nonsilent somatic mutations (affecting 1,042 genes) were identified ( Supplementary Table 3 ), a mutation rate comparable to those of most adult solid tumors 13 (Supplementary Fig. 1 ). We extensively validated 362 candidate somatic mutations with Sanger sequencing (true-positive rate = 93.1%, Supplementary Table 3 ). Intratumoral clonality analysis showed that both biclonal and multiclonal signatures existed in ESCC (Supplementary Fig. 2) . Cross comparing the WES with RNA-seq data from the same tumors revealed that 61% of the mutated genes were transcribed ( Supplementary Table 4 ), which is comparable to the value reported for breast cancer 14 .
To evaluate the prevalence of these mutated genes from discovery cohort, we sequenced all of their coding exons with 119 additional matched ESCC germline/tumors, as well as 10 ESCC cell lines (frequency cohort, mean coverage 111×, Supplementary Tables 1b  and 2b ). To cover more comprehensively the mutational events in this disease, we also included an additional 277 genes that were discovered in the previous WES study of 12 ESCCs 8 or causally implicated in other human cancers (Cancer Gene Census; Supplementary  Table 5 ). As a result, a total of 1,847 nonsilent somatic mutations were identified, with an average of 15 mutations per case (truepositive rate = 96.2%, Fig. 1a ; Supplementary Table 6 ). Notably, the mutational spectrums from the discovery and frequency cohorts are almost identical ( Supplementary Fig. 3a ), suggesting that our targeted sequencing approach comprehensively unmasked most of the mutational events in DNA-coding regions in ESCC. Of note, trinucleotide-signature analysis suggested that DNA cytidine deaminase APOBEC3B is responsible for ESCC mutagenesis [15] [16] [17] (Fig. 1b and l e t t e r s Supplementary Fig. 3b ), and indeed, APOBEC3B expression was clearly upregulated in ESCC tumors ( Fig. 1c ). We observed that 609 genes were mutated in two or more samples, with 62 genes mutated at a frequency over 5% ( Supplementary Fig. 3c ). To identify mutations conferring selective growth advantages ('driver mutations'), we applied the algorithm MutSigCV 13 , which corrects for variation by incorporating patient-specific mutational spectrum and gene-specific background mutational burden and also by measuring gene expression and replication time. As a result, we calculated that 13 genes were significantly mutated (false-discovery rate q < 0.2). Notably, many of these mutated genes had not previously been implicated in ESCC.
To interrogate SCNV in ESCC, we examined 22 tumors with a SNP array (18 from the discovery cohort), as well as 59 samples with array CGH 18 . We further comprehensively analyzed three additional SNP-array data sets measuring primary ESCCs 4, 11, 12 ( Supplementary  Table 7 ), resulting in a total of 184 analyzable primary ESCC samples. We focused on focal SCNV, defined as narrow regions (typically <100 kb) showing high-amplitude copy number changes (Online Methods), which have a higher probability of containing cancer genes. This approach identified 14 recurrent focal SCNVs, with the most frequent amplification peak spanning the CCND1 gene on 11q13.2 ( Supplementary Table 7 ). Additional peaks involving important cancer genes such as EGFR, MYC, KRAS and CDKN2A were found. Notably, FGFR1 was shown to be frequently amplified, which has not been reported before in ESCC. To confirm this observation, we examined an additional 53 ESCC tumors with fluorescence in situ hybridization (FISH) and found that FGFR1 was amplified in 11 samples ( Fig. 2a and Supplementary Table 7 ). Furthermore, with immunohistochemistry (IHC), we found that the FGFR1 protein was upregulated in 17.3% ESCC tumors ( Fig. 2b and Supplementary  Table 8a ). Given that FGFR amplification is predictive of sensitivity to targeted inhibitors in several other solid tumors 19 , our results suggest that FGFR1 is a potential therapeutic target in ESCC.
We next sought to understand dysregulated pathways in ESCC. As we previously reported protein alterations in ESCC using meta-analysis 20 , here we also took into account protein overexpression evidence. Mitogen-activated protein kinase (MAPK) (P = 0.0005, Fig. 2d , Supplementary Table 9a and Online Methods) and phosphatidylinositol 3-kinase (PI3K) pathways (P = 0.0004) are augmented by multiple mechanisms: (i) amplification and overexpression of RTKs, KRAS and PIK3CA; (ii) activating mutations of ERBB4 and PIK3CA; (iii) inactivating mutations of PTEN, MAP3K13 and MAP3K15. In addition, IL7R amplification and JAK1 mutations were identified, which will likely activate JAK-STAT3 signaling (P = 0.0006).We previously showed that p-STAT3 is elevated in ESCC 21 , which transforms esophageal epithelial cells cooperatively with amplified SOX2 (ref. 22) . Cell cycle progression ( Fig. 2e , P = 1.63 × 10 −5 ) is altered mostly by CCND1 amplification, CDKN2A deletion or mutation and TP53 mutation. As a negative regulator of c-Myc, frequent FBXW7 mutations were observed in our investigation ( Fig. 2c) , confirming a recent report of this gene in ESCC 8 . We next examined FBXW7 protein expression with IHC and found its mutation led to loss of the protein (Fig. 2c) . Moreover, in an additional cohort (n = 40), we determined that FBXW7 protein was downregulated in 33% of tumors npg l e t t e r s ( Supplementary Fig. 4 and Supplementary  Table 8b ), further demonstrating its relevance in ESCC. Another prominent enrichment of mutated genes in ESCC are those implicated in epigenetic modifications (P = 0.0013, Fig. 2f and Supplementary Table 9b ), such as members of the SWI/SNF complex (ARID2 and PBRM1), histone methyltransferases KMT2D and KMT2C, and demethylase KDM6A. ZNF750 is a poorly studied nuclear protein that is upregulated in differentiated skin keratinocytes 23, 24 . We observed that ZNF750 was significantly mutated in ESCC (q = 1.24 × 10 −6 , Fig. 3a) . Notably, analysis of public data sets revealed that ZNF750 is largely mutated in squamous cell carcinomas, with most of them presenting truncating mutations ( Supplementary Fig. 5b ). In line with this, ESCC harbors a much higher mutational burden affecting ZNF750 than esophageal adenocarcinoma. The similar pattern was also observed when comparing lung SCC to lung adenocarcinoma. From Cancer Cell Line Encyclopedia (CCLE) results, we found that ZNF750 mRNA showed higher expression in ESCC and upper aerodigestive squamous cell carcinoma (UASCC) than any other nonsquamous cancer cell lines ( Supplementary Fig. 5a ). These data suggest that ZNF750 somatic mutations are biologically relevant in squamous cell malignancy. In addition, we found that ZNF750 was focally deleted in 3.4% of ESCC tumors (Fig. 3b) , and ZNF750 mRNA expression was lower in esophageal tumors compared with normal tissue (Fig. 3c) . Moreover, our IHC approach revealed that in normal esophageal epithelial, ZNF750 protein showed strong nuclear staining in the suprabasal layer of cells and above; whereas in ESCC tumors, ZNF750 showed much weaker expression ( Fig. 3d and Supplementary Table 8c ). Notably, in ESCC cells with wild-type endogenous ZNF750 expression, depletion of ZNF750 promoted cell proliferation ( Fig. 3e) , associated with a decreased expression of the genes implicated in late epithelial differentiation, whereas ectopic expression of ZNF750 led to the upregulation of these genes (Supplementary Fig. 5c ).
Moreover, 12-O-tetra-decanoylphorbol-13-acetate (TPA), a wellcharacterized differentiation-induction agent which has also been commonly used to promote ESCC differentiation 25, 26 , markedly enhanced ZNF750 expression ( Fig. 3f) , with a concomitant inhibition of cell proliferation ( Supplementary Fig. 5d ). Notably, ectopic expression of ZNF750 further promoted the TPA-induced growth suppression ( Fig. 3g) . Collectively, these results indicate that ZNF750 might function as a tumor suppressor in ESCC through regulating squamous cell differentiation.
The FAT family of proteins is comprised of FAT1, FAT2, FAT3 and FAT4, which are cadherin superfamily members encoded by genes homologous to the Drosophila gene fat. Very recently, FAT1 was reported as a tumor suppressor in glioblastoma, colorectal cancer, and head and neck squamous cell carcinoma (HNSCC) 27 . However, the precise role of FAT genes in cancer still remains inconclusive and needs further characterization 28, 29 . Our data revealed that ESCC harbored very frequent, mutually exclusive truncating mutations affecting FAT1, FAT2 and FAT3 compared to other solid tumors (Fig. 4a,b and Supplementary Fig. 6a ). Among FAT1-mutated tumors, two samples were also analyzed with SNP array, and we discovered loss of heterozygosity of the FAT1 gene in both tumors ( Supplementary  Fig. 6b ), supporting Knudson's two-hit model. We next found that homozygous deletions of FAT1 occurred in 3.4% of ESCCs (Fig. 4c) . Furthermore, IHC staining demonstrated that FAT1 protein expression was downregulated in ESCC ( Fig. 4d) . To study the function of FAT gene inactivation in ESCC, we first silenced wild-type FAT1 expression with siRNA, and observed an increase in cell proliferation ( Fig. 4e) npg l e t t e r s significantly inhibited both cell proliferation (P = 0.001) and colony formation in soft agar (P = 0.019, Supplementary Fig. 7) . Depletion of FAT2 with shRNA promoted ESCC growth in vivo ( Fig. 4f,g) . Together, the presence of mutations and alterations in protein expression with functional consequences strongly suggest that FAT1 and FAT2 likely encode tumor suppressors that are frequently disrupted in ESCC.
In mammalian cells, the chief mediator of protein nuclear export is exportin 1 (XPO1). Because XPO1 exports a number of tumor suppressors, targeting it has been considered as an antineoplastic approach 30 . We found one missense substitution, D624G, affecting XPO1. Notably, this mutation is identical to the one discovered in chronic lymphocytic leukemia 31 . Structural modeling analysis revealed that Asp624 is part of the site at which XPO1 binds conventional cargo, such as Snurportin 32, 33 ; for example, Asp624 forms a salt bridge with Snurportin's Lys144 (Fig. 5a) . D624G substitution presumably reduces the affinity of interactions owing to loss of the salt bridge. This alteration may accelerate the turnover of XPO1 from the 'bound' to 'unbound' state and enhance its exporting efficiency. We next analyzed the expression of XPO1's mRNA and protein and found that they were frequently overexpressed in ESCC tumor samples ( Fig. 5b,c) . Moreover, XPO1 overexpression positively correlated with larger tumor size (P = 0.016, Supplementary Table 8d ). Notably, the XPO1-mutated tumor also showed upregulated protein expression compared with the matched adjacent normal esophageal epithelium, indicating a gain-of-function phenotype (Fig. 5b) . We next silenced XPO1 gene expression with shRNA, and noticed the induction of apoptosis (as evidenced by cleaved PARP) and retardation of cell proliferation (Fig. 5d,e ). To explore whether XPO1 is druggable in ESCC, we treated ESCC cells with a newly developed oral, smallmolecule inhibitor, KPT-330, which specifically blocks XPO1 function by binding to the active-site Cys528 (refs. [34] [35] [36] . Submicromolar concentrations of KPT-330 inhibited ESCC cell proliferation and induced marked apoptosis (Fig. 5f,g) . Inhibition of XPO1 with either shRNA or KPT-330 altered the expression of its known cargos (such as P53), as well as indirect targets including Cyclin D1, c-Myc, PUMA and BIM, which might be a result of various mechanisms that we and others have recently identified [37] [38] [39] [40] [41] [42] [43] (Fig. 5e,h) . Given that frequent overexpression of XPO1 protein is clinically relevant [44] [45] [46] [47] and functionally contributes to the cellular malignant phenotype, targeting XPO1 in those patients with XPO1 upregulation might offer potential benefits in ESCC.
In an effort to identify therapeutic targets in ESCC, we correlated genomic mutations, amplifications, and mRNA and protein upregulation [48] [49] [50] [51] in both primary tumors and cancer cell lines, with novel targeted therapeutic approaches. We chose those targeting approaches that have been approved for clinical use 52, 53 or are under evaluation in clinical trials (see URLs section below). As a result, we identified 31 (Supplementary Tables 10-12) . Importantly, most of the targets and pathways discovered here have not previously been considered as targets in ESCC. These results suggest that many potential therapeutic targets exist in ESCC that need further investigation.
In summary, we report the mutational landscape of 139 ESCCs as well as an SCNV overview of 184 ESCC cases. A number of mutated genes and altered pathways not previously associated with ESCC were identified with statistical and biological evidence of growth selection, indicating that they likely contribute to esophageal tumorigenesis. In addition to XPO1, our analysis proposes many potential therapeutic targets, which offer opportunities to address a typically chemoresistant cancer. I298N  G569V  S1209L  R1376T  V1661I  I2205V  I3329M  H2411Y   W813C  E834K  G1378R  R1445G  D1547N  H2670D  F3600L  D3606N  P2689Q  D1234Y  D1272H   I1377N  V2067M  E2659G  S3046F  N3434I  H3762N  G4102R  R4479T  K351fs  K360fs  Q600X  S2033X  R2726X  E2949fs  Q3825X  K3040fs  Y658fs N710fs
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Sample collection and histopathological assessment. ESCC tissue samples were collected from Cancer Institute/Hospital, Chinese Academy of Medical Sciences (CAMS) and Linxian Cancer Hospital. All the samples used in this study were residual specimens collected after diagnosis. No patient received treatment before sample collection. Matched normal tissues (germline controls) were collected from adjacent esophageal epithelial five centimeters away from the border of surgical area. All tumor/normal samples were subject to hematoxylin staining and histopathological review to assess the presence of tumor cells, normal esophageal epithelial cells, lymphocytic infiltration and necrotic cells. Tumor cellularity was scored visually in a semiquantitative fashion and only those tumors with >70% malignant cells were chosen for DNA/RNA sequencing. All patients signed independent informed consent forms for the sampling and molecular analyses. This study has been approved by the Ethics Committee/Institutional Review Board of Cancer Institute/ Hospital, CAMS and Linxian Cancer Hospital.
Cell culture and related chemicals. All of the human ESCC cell lines and 293T cells were grown in Dulbecco modified Eagle medium (DMEM) with 10% fetal calf serum (FCS) and were maintained at 37 °C in a 5% CO2 airhumidified incubator. ESCC cell lines KYSE30, KYSE50, KYSE70, KYSE110, KYSE150, KYSE450, KYSE510 and YES2 were kindly shared by Y. Shimada (Kyoto University). KYSE140 and KYSE180 were generously provided by Xin-Yuan Guan (Department of Clinical Oncology, University of Hong Kong). All ESCC cell lines were regularly authenticated and tested for absence of mycoplasma recently 55 . TPA was purchased from Sigma-Aldrich. KPT-330 was provided by Karyopharm Therapeutics.
Short-term cell proliferation assays. Cells were placed into 96-well plates at 2 × 10 3 to 4 × 10 3 cells/well and incubated for an additional 4-5 days in DMEM with 1-10% FCS. The MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay was performed as described previously 56 .
Assessment of apoptosis.
Annexin V assay (BD Pharmingen) was performed to assess apoptosis according to the manufacturer's instructions. Briefly, cells were harvested after exposure to KPT-330, washed twice with PBS, incubated with FITC/PE-conjugated Annexin V and propidium iodide/7-AAD for 15 min, and measured by flow cytometry (FCM) using FACScan (Becton Dickinson).
Xenografts in NOD/SCID mice.
A total of six male NOD/SCID mice at 5-6 weeks of age were provided by Cancer Science Institute of Singapore. We mixed 2 × 10 6 of KYSE150 cells (Scramble and shFAT2 stable cells) with 100 µl of Matrigel solution (BD Biosciences) per injection, and the mixture was injected subcutaneously on the upper flanks of NOD/SCID mice. Mice were randomly allocated to either Scramble or shFAT2 groups. After 19 d, the mice were killed to weigh and analyze the dissected tumors. No blinding of investigators was performed. No statistical methods were used to determine the sample size of mice. Animal study was done in compliance with ethical regulations of Institutional Animal Care and Use Committee of National University of Singapore.
Reverse transcription and real-time PCR.
Total RNA was reverse transcribed to cDNA with Superscript III (Invitrogen) according to manufacturer's protocols. Real-time PCR reactions were performed in triplicate for every sample using the 7500 Real-time PCR System (Applied Biosystems). Primers are listed in Supplementary Table 13a .
Lentiviral-based expression and shRNA vectors.
The open reading frame (ORF) of human FAT1 and ZNF750 transcripts were generously provided by T. Chan's group from Memorial Sloan-Kettering Cancer Center 27 and P. Khavari's group from Veterans Affairs Palo Alto Healthcare System 24 , respectively. Both ORFs were subcloned into lentiviral-based expression vector SHC003 (Sigma-Aldrich) using NheI and FseI cloning sites. SHC003-Turbo-GFP was used as control (Sigma-Aldrich). The lentiviral-based shRNA vectors (shXPO1 and shFAT2 sequences are listed in Supplementary Table 13b) were generated with PLKO.1 backbone (Sigma-Aldrich) using AgeI and EcoRI cloning sites. SHC002-Scramble shRNA was used as control (Sigma-Aldrich). The cloning primers are listed in Supplementary Table 13c .
Transfections, viral particle production and infection. ESCC cells and 293T
cells were transfected with Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen). siRNA sequences targeting FAT1 or ZNF750 are listed in Supplementary Table 13d . Lentiviral particles were produced and harvested using MISSION Lentiviral Packaging System (Sigma-Aldrich). The ESCC cells were infected with the lentiviral particles for 48 h in the presence of 8 µg/ml polybrene (Sigma-Aldrich).
Whole-exome sequencing (WES) and targeted deep sequencing (TDS).
We sonicated 1.5 µg (WES) or 1 µg (TDS) of genomic DNA to generate a peak target size of 200 bp. DNA was captured using the SureSelect Human All Exon 50M (WES) or customized cRNA beads ( Supplementary Table 14 , TDS) according to the manufacturers' protocols. Captured DNAs were subjected to massively parallel sequencing using HiSeq2000 with 75-to 100-bp paired-end reads.
To detect somatic nucleotide variations from WES, we used previously described in-house algorithms [57] [58] [59] . Briefly, the sequencing reads were aligned to a human reference genome (hg19) using BWA version 0.5.8 with default parameters. PCR duplicate reads were removed using Picard (http://www. picard.sourceforge.net/). Before summarizing base-call data, we eliminated low-quality reads, including those reads that had either more than five mismatches to the reference sequences or whose mapping quality was less than 30. The significance of each candidate mutation was evaluated by Fisher's exact test by enumerating the number of the reference base and the candidate SNV in both tumor and germline control. Candidate mutations with P values less than 0.01 were adopted as provisional candidates for somatic mutations. In addition, the following nucleotide positions were eliminated from further analysis: those at which the depth was less than 10 in either tumor or control, or where the most frequent SNV or indel accounted for less than 7% of all reads in the tumor. Germline SNPs were eliminated using sequencing data from paired normal DNA. Finally, a list of candidate somatic mutations was generated by excluding synonymous SNVs and other variants registered in dbSNP131, the 1000 Genomes Project or our in-house SNP database constructed from 180 patients 57, 58 .
To make somatic mutation calling with the TDS approach of the frequency cohort more rigorous, the following nucleotide positions were further removed: those at which the supporting depth from both directions was less than 5 in either tumor or control, or where the most frequent SNV or indel accounted for less than 8% of all reads in the tumor.
To detect probable somatic mutations of ESCC cell lines that do not have paired germline controls, nucleotide positions were further removed if the supporting depth from both directions was less than 5, the most frequent SNV or indel accounted for less than 8% of all reads, or the frequency of the SNV or indel was between 45% and 55% without copy number abnormalities.
Tissue microarray (TMAs) and immunohistochemistry (IHC). Paraffinembedded tissue microarrays (TMAs) containing 50 primary ESCC tumors and the corresponding normal epithelia were used for IHC. For each case, histologically normal tissues adjacent to tumors were examined as control. TMA slides were initially deparaffinized using xylene, rehydrated with xylene and ethanol, immersed in 3% hydrogen peroxide solution for 10 min, heated with citrate at 95 °C for 25 min and cooled at room temperature for 60 min. The slides were incubated overnight at 4 °C with the following antibodies: XPO1 (sc-5595, Santa Cruz Biotechnology; 1:50), ZNF750 (HPA023012, Sigma-Aldrich; 1:100), FAT1 (HPA023882, Sigma-Aldrich; 1:25), or FBXW7 (H00055294-M02, Abnova; 1:200), FGFR1 (9740, Cell Signaling Technology, 1:25) and visualized using PV-9000 Polymer Detection System following the manufacturer's instructions (Golden Bridge International). Counterstaining was carried out with hematoxylin. The results were separately evaluated by two pathologists. Protein expression was evaluated on the basis of staining intensity, graded on the following scale: 0 (negative), 1 (weak), 2 (moderate) and 3 (strong).
Protein blotting. Cells were lysed on ice with lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Nonidet P-40) containing complete protease and npg
